Monoclonal antibodies (mAb) neutralizing CD39 ectonucleotidase activity, such as ES002023 (Elpiscience Biopharma, Ltd.), SRF617 (Surface Oncology) and TTX-030 (Tizona Therapeutics), have been developed to boost extracellular ATP anti-tumor responses and curb the immunosuppressive effects of adenosine in tumors. This evidence concerns the gene ENTPD1 and neoplasm.